cancer of unknown primary
Cancer Dx Firm C2i Genomics Raises $100M in Financing
The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.
CRISPR-Cas9 Genome Editing Can Lead to Extensive Chromosome Rearrangements
A study showed that chromothripsis, a mutational process that can lead to congenital disease and cancer, can result from on-target editing with Cas9.
Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit
Premium
Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.
GenomeWeb Index Gains 49 Percent in 2020, Outperforming Wider Markets
Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.
Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.